Journal of Pharmacology and Pharmacotherapeutics

MINI REVIEW
Year
: 2013  |  Volume : 4  |  Issue : 4  |  Page : 230--237

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects


Afroz Abidi 
 Department of Pharmacology, Subharti Medical College, Subhartipuram, Meerut Bypass, Meerut, Uttar Pradesh, India

Correspondence Address:
Afroz Abidi
C/O S.I.S Abidi, Mass Products India Ltd, Mill Road, Aishbagh, Lucknow - 226 004, Uttar Pradesh
India

Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.


How to cite this article:
Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.J Pharmacol Pharmacother 2013;4:230-237


How to cite this URL:
Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother [serial online] 2013 [cited 2020 Aug 5 ];4:230-237
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2013;volume=4;issue=4;spage=230;epage=237;aulast=Abidi;type=0